Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$4.44 -6.1%	$7.08	$4.36 ▼ $68.70	$8.56M	0.42	115,016 shs	88,104 shs
KPTI Karyopharm Therapeutics	$3.77 -4.3%	$4.32	$3.51 ▼ $16.95	$34.04M	0.28	151,064 shs	301,151 shs
RANI Rani Therapeutics	$0.50 -5.3%	$0.53	$0.39 ▼ $3.75	$33.37M	-0.02	4.76 million shs	1.12 million shs
XLO Xilio Therapeutics	$0.68 +2.6%	$0.69	$0.62 ▼ $1.70	$34.33M	-0.15	359,053 shs	723,044 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	0.00%	+0.21%	-3.07%	-40.30%	-91.83%
KPTI Karyopharm Therapeutics	0.00%	+0.25%	-13.41%	-35.93%	-67.57%
RANI Rani Therapeutics	0.00%	-0.08%	-18.01%	-13.87%	-76.64%
XLO Xilio Therapeutics	0.00%	+2.00%	-9.69%	-9.30%	-23.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLRB Cellectar Biosciences	2.7935 of 5 stars	3.2	5.0	0.0	0.6	1.7	1.3
KPTI Karyopharm Therapeutics	3.4433 of 5 stars	3.4	0.0	4.6	0.6	2.5	0.6
RANI Rani Therapeutics	2.563 of 5 stars	3.5	1.0	0.0	4.0	1.7	0.6
XLO Xilio Therapeutics	3.4806 of 5 stars	3.7	4.0	0.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLRB Cellectar Biosciences	2.33	Hold	$375.00	8,345.95% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$37.40	892.04% Upside
RANI Rani Therapeutics	3.00	Buy	$7.33	1,366.67% Upside
XLO Xilio Therapeutics	3.33	Buy	$3.00	341.05% Upside

Current Analyst Ratings Breakdown

Latest CLRB, KPTI, XLO, and RANI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	XLO Xilio Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	XLO Xilio Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$2.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
5/16/2025	RANI Rani Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$14.00 ➝ $4.00
5/14/2025	CLRB Cellectar Biosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$8.98 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.22	N/A	N/A	($22.10) per share	-0.17
RANI Rani Therapeutics	$1.03M	30.68	N/A	N/A	$0.06 per share	8.33
XLO Xilio Therapeutics	$6.34M	5.56	N/A	N/A	$0.40 per share	1.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLRB Cellectar Biosciences	-$44.58M	-$21.92	N/A	N/A	N/A	N/A	-619.70%	-158.04%	8/14/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/11/2025 (Estimated)
RANI Rani Therapeutics	-$30.02M	-$0.91	N/A	N/A	N/A	N/A	-2,272.39%	-85.38%	N/A
XLO Xilio Therapeutics	-$58.24M	-$0.84	N/A	N/A	N/A	-585.54%	-262.69%	-64.01%	8/14/2025 (Estimated)

Latest CLRB, KPTI, XLO, and RANI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CLRB Cellectar Biosciences	-$3.70	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	XLO Xilio Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million
8/7/2025	Q2 2025	RANI Rani Therapeutics	-$0.19	-$0.18	+$0.01	-$0.18	N/A	N/A
5/13/2025	Q1 2025	CLRB Cellectar Biosciences	-$5.10	-$3.90	+$1.20	-$0.14	N/A	N/A
5/13/2025	Q1 2025	RANI Rani Therapeutics	-$0.22	-$0.22	N/A	-$0.22	N/A	$0.20 million
5/13/2025	Q1 2025	XLO Xilio Therapeutics	$0.10	-$0.18	-$0.28	-$0.18	$42.00 million	$2.93 million
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLRB Cellectar Biosciences	N/A	2.47	2.47
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
RANI Rani Therapeutics	2.75	0.88	0.88
XLO Xilio Therapeutics	N/A	1.96	1.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLRB Cellectar Biosciences	16.41%
KPTI Karyopharm Therapeutics	66.44%
RANI Rani Therapeutics	30.19%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
CLRB Cellectar Biosciences	5.04%
KPTI Karyopharm Therapeutics	2.75%
RANI Rani Therapeutics	45.08%
XLO Xilio Therapeutics	6.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLRB Cellectar Biosciences	10	1.81 million	1.72 million	Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.40 million	Optionable
RANI Rani Therapeutics	110	63.21 million	34.71 million	Optionable
XLO Xilio Therapeutics	70	51.78 million	48.52 million	Not Optionable

CLRB, KPTI, XLO, and RANI Headlines

Recent News About These Companies

Brokers Set Expectations for XLO Q2 Earnings

August 10 at 2:19 AM | americanbankingnews.com

Leerink Partners Begins Coverage on Xilio Therapeutics (NASDAQ:XLO)

August 8 at 2:41 AM | americanbankingnews.com

Leerink Partners Initiates Coverage of Xilio Therapeutics (XLO) with Outperform Recommendation

August 7, 2025 | msn.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

James Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) Stock

June 19, 2025 | insidertrades.com

Xilio Therapeutics expands board, elects new director

June 12, 2025 | investing.com

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors

June 10, 2025 | quiverquant.comQ

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

June 10, 2025 | globenewswire.com

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

June 5, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

June 2, 2025 | globenewswire.com

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...

June 2, 2025 | stockhouse.com

Xilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C Warrants

June 2, 2025 | quiverquant.comQ

Xilio Therapeutics Announces Proposed Public Offering

June 2, 2025 | globenewswire.com

Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial

May 31, 2025 | insidermonkey.com

Xilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal Cancer

May 31, 2025 | quiverquant.comQ

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 31, 2025 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB, KPTI, XLO, and RANI Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

$4.44 -0.29 (-6.13%)

Closing price 04:00 PM Eastern

Extended Trading

$4.51 +0.07 (+1.67%)

As of 07:56 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Karyopharm Therapeutics NASDAQ:KPTI

$3.77 -0.17 (-4.31%)

Closing price 04:00 PM Eastern

Extended Trading

$3.85 +0.08 (+2.12%)

As of 07:52 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Rani Therapeutics NASDAQ:RANI

$0.50 -0.03 (-5.30%)

Closing price 04:00 PM Eastern

Extended Trading

$0.51 +0.01 (+2.60%)

As of 07:22 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Xilio Therapeutics NASDAQ:XLO

$0.68 +0.02 (+2.59%)

Closing price 04:00 PM Eastern

Extended Trading

$0.67 -0.01 (-1.65%)

As of 05:24 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time